Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2007-04-01 (19 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LIMOGES (87100), Haute-Vienne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE DE BEAUBLANC : revenue, balance sheet and financial ratios
SELARL PHARMACIE DE BEAUBLANC is a French company
founded 19 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LIMOGES (87100),
this company of category PME
shows in 2023 a revenue of 3.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE DE BEAUBLANC (SIREN 494792088)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
3 403 104 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
132 551 €
42 067 €
109 339 €
207 752 €
93 871 €
95 942 €
51 138 €
46 387 €
92 470 €
EBITDA
N/C
N/C
166 996 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
3.2%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE DE BEAUBLANC generates positive net income of 133 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 92 k€ -> 133 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
132 551 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 50%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 54%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
50.457%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
54.495%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE DE BEAUBLANC
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
102.554
121.722
118.217
99.812
98.407
80.744
66.787
60.463
50.457
Financial autonomy
44.855
40.346
41.79
44.083
45.125
46.804
50.871
51.423
54.495
Repayment capacity
None
None
None
None
None
None
6.681
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
4.414%
None%
None%
Sector positioning
Debt ratio
50.462025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average
In 2025, the debt ratio of SELARL PHARMACIE DE BEAUB... (50.46) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
54.49%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of SELARL PHARMACIE DE BEAUB... (54.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
6.68 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of SELARL PHARMACIE DE BEAUB... (6.68) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 110.84. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
110.838
Liquidity indicators evolution SELARL PHARMACIE DE BEAUBLANC
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
95.419
112.788
129.725
108.131
143.526
147.91
130.269
110.852
110.838
Interest coverage
None
None
None
None
None
None
1.554
None
None
Sector positioning
Liquidity ratio
110.842025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch
In 2025, the liquidity ratio of SELARL PHARMACIE DE BEAUB... (110.84) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
1.55x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of SELARL PHARMACIE DE BEAUB... (1.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE DE BEAUBLANC
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
314 243 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
30
0
0
Customer payment term (days)
0
0
0
0
0
0
5
0
0
Supplier payment term (days)
0
0
0
0
0
0
47
0
0
Positioning of SELARL PHARMACIE DE BEAUBLANC in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE DE BEAUBLANC is estimated at
2 105 588 €
(range 1 428 862€ - 3 303 958€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1428k€2105k€3303k€
2 105 588 €Range: 1 428 862€ - 3 303 958€
NAF 5 année 2025
Valuation method used
Net Income Multiple
132 551 €
×
15.9x
=2 105 588 €
Range: 1 428 862€ - 3 303 958€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE DE BEAUBLANC with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE DE BEAUBLANC
What is the revenue of SELARL PHARMACIE DE BEAUBLANC ?
The revenue of SELARL PHARMACIE DE BEAUBLANC in 2023 is 3.4 M€.
Is SELARL PHARMACIE DE BEAUBLANC profitable?
Yes, SELARL PHARMACIE DE BEAUBLANC generated a net profit of 133 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE DE BEAUBLANC ?
The headquarters of SELARL PHARMACIE DE BEAUBLANC is located in LIMOGES (87100), in the department Haute-Vienne.
Where to find the tax return of SELARL PHARMACIE DE BEAUBLANC ?
The tax return of SELARL PHARMACIE DE BEAUBLANC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE DE BEAUBLANC operate?
SELARL PHARMACIE DE BEAUBLANC operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart